By Britain Eakin ( August 26, 2021, 12:25 PM EDT) -- The Federal Circuit on Thursday reversed a $1.1 billion judgment against Gilead's Kite Pharma Inc. for infringing Bristol-Myers cancer immunotherapy patent, ruling that the patent is invalid because it lacks adequate written description support....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.